scholarly journals Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease

2020 ◽  
Vol Volume 14 ◽  
pp. 931-938 ◽  
Author(s):  
Darrell E White ◽  
Yang Zhao ◽  
Hemalatha Jayapalan ◽  
Pattabhi Machiraju ◽  
Ramu Periyasamy ◽  
...  
Keyword(s):  
Dry Eye ◽  
Dry Eye Disease ◽  
Physician Satisfaction ◽  
Eye Disease ◽  
Anti Inflammatory ◽  
Topical Medications

scholarly journals Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease

2020 ◽  
Vol Volume 14 ◽  
pp. 875-883 ◽  
Author(s):  
Darrell E White ◽  
Yang Zhao ◽  
Hemalatha Jayapalan ◽  
Pattabhi Machiraju ◽  
Ramu Periyasamy ◽  
...  
Keyword(s):  
Dry Eye ◽  
Treatment Satisfaction ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Anti Inflammatory ◽  
Topical Medications

scholarly journals Cyclosporine use in “dry eye” syndrome

2019 ◽  
Vol 12 (3) ◽  
pp. 75-82
Author(s):  
Inna A. Riks
Keyword(s):  
Literature Review ◽  
Dry Eye ◽  
Dry Eye Disease ◽  
Dry Eye Syndrome ◽  
Eye Disease ◽  
Anti Inflammatory

This literature review focuses on the need for anti-inflammatory therapy for dry eye disease (DED). Causes of development and mechanisms of pathogenesis of DED are presented. Principles of action of various groups of anti-inflammatory medications, as well as recommendations for cyclosporine use of are described. The results of studies on cyclosporine efficacy are highlighted, principles of cyclosporin prescription in DED are listed.

scholarly journals Tear Film – Physiology and Disturbances in Various Diseases and Disorders

2021 ◽  
Author(s):  
Dorota Kopacz ◽  
Łucja Niezgoda ◽  
Ewa Fudalej ◽  
Anna Nowak ◽  
Piotr Maciejewicz
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Fluid Layer ◽  
Dynamic Balance ◽  
Tear Film ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Immune Protection ◽  
Topical Medications

The tear film is a thin fluid layer covering the ocular surface. It is responsible for ocular surface comfort, mechanical, environmental and immune protection, epithelial health and it forms smooth refractive surface for vision. The traditional description of the tear film divides it into three layers: lipid, aqueous and mucin. The role of each layer depends on the composition of it. Tear production, evaporation, absorption and drainage concur to dynamic balance of the tear film and leads to its integrity and stability. Nonetheless, this stability can be disturb in tear film layers deficiencies, defective spreading of the tear film, in some general diseases and during application of some general and/or topical medications. Dry eye disease is the result of it. In this review not only physiology of the tear film is presented. Moreover, we would like to discuss the influence of various diseases and conditions on the tear film and contrarily, spotlight tear film disorders as a manifestation of those diseases.

Anti-inflammatory therapy for dry eye disease: rationale and strategy

2013 ◽  
pp. 243-243 ◽  
Author(s):  
John Sheppard ◽  
Niraj Shah ◽  
Giovanni DiSandro ◽  
Brianne Anthony
Keyword(s):  
Dry Eye ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Anti Inflammatory

scholarly journals GlicoPro, Novel Standardized and Sterile Snail Mucus Extract for Multi-Modulative Ocular Formulations. New Perspective in Dry Eye Disease Management

Pharmaceutics ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2139
Author(s):  
Rita Mencucci ◽  
Giovanni Strazzabosco ◽  
Virginia Cristofori ◽  
Andrea Alogna ◽  
Daria Bortolotti ◽  
...  
Keyword(s):  
Dry Eye ◽  
Sodium Hyaluronate ◽  
Ophthalmic Solution ◽  
Dry Eye Disease ◽  
Mass Spectrometry Analysis ◽  
Corneal Epithelial Cell ◽  
Eye Disease ◽  
Corneal Cells ◽  
Anti Inflammatory

This study aimed to evaluate the mucoadhesive and regenerative properties of a novel lubricating multimolecular ophthalmic solution (GlicoPro®) extracted from snail mucus and its potential anti-inflammatory and analgesic role in the management of dry eye disease (DED). GlicoPro bio-adhesive efficacy was assessed using a lectin-based assay, and its regenerative properties were studied in a human corneal epithelial cell line. In vitro DED was induced in human corneal tissues; the histology and mRNA expression of selected genes of inflammatory and corneal damage biomarkers were analyzed in DED tissues treated with GlicoPro. A higher percentage of bio-adhesivity was observed in corneal cells treated with GlicoPro than with sodium hyaluronate-based compounds. In the scratch test GlicoPro improved in vitro corneal wound healing. Histo-morphological analysis revealed restoration of cellular organization of the corneal epithelium, microvilli, and mucin network in DED corneal tissues treated with GlicoPro. A significant reduction in inflammatory and ocular damage biomarkers was observed. High-performance liquid chromatography-mass spectrometry analysis identified an endogenous opioid, opiorphin, in the peptide fraction of GlicoPro. In conclusion, GlicoPro induced regeneration and bio-adhesivity in corneal cells; moreover, considering its anti-inflammatory and analgesic properties, this novel ophthalmic lubricating solution may be an innovative approach for the management of DED.

scholarly journals Current treatment modalities for dry eye disease

2021 ◽  
Vol 21 (1) ◽  
pp. 18-23
Author(s):  
E.B. Tatarnikova ◽  
◽  
O.I. Krivosheina ◽  
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Tear Film ◽  
Current Treatment ◽  
Dry Eye Disease ◽  
Treatment Modalities ◽  
Eye Disease ◽  
Published Data ◽  
Eye Drops ◽  
Anti Inflammatory

For many years, dry eye disease (DED) is a common ophthalmic condition associated with ocular surface damage and loss of homeostasis of the tear film. The key pathogenic factors of DED are tear film instability and tear hyperosmolarity, ocular surface inflammation and damage, and neurosensory alterations. Current treatment for DED consists of non-medical therapies, tear substitutes, anti-inflammatory agents, and surgical procedures. These treatments improve disease course and quality of life. However, these treatments are largely palliative as long-term (and even life-long) installation of eye drops is required. Modern and effective treatments for DED are needed. This paper reviews domestic and foreign published data on the important therapies for DED and novel tools to promote symptom relief. These data are required for the understanding of the pharmacological effects of various drug classes prescribed for DED and early treatment initiation. Keywords: dry eye disease, tear replacement therapy, anti-inflammatory treatment, surgery, hyaluronic acid, preservatives. For citation: Tatarnikova E.B., Krivosheina O.I. Current treatment modalities for dry eye disease. Russian Journal of Clinical Ophthalmology. 2021;21(1):18–23. DOI: 10.32364/2311-7729-2021-21-1-18-23.

scholarly journals Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation

Pharmaceutics ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 1698
Author(s):  
Ana López-Machado ◽  
Natalia Díaz-Garrido ◽  
Amanda Cano ◽  
Marta Espina ◽  
Josefa Badia ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ex Vivo ◽  
Visual Disturbance ◽  
Nasolacrimal Duct ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Lipid Film ◽  
Anti Inflammatory

Dry eye disease (DED) is a high prevalent multifactorial disease characterized by a lack of homeostasis of the tear film which causes ocular surface inflammation, soreness, and visual disturbance. Conventional ophthalmic treatments present limitations such as low bioavailability and side effects. Lactoferrin (LF) constitutes a promising therapeutic tool, but its poor aqueous stability and high nasolacrimal duct drainage hinder its potential efficacy. In this study, we incorporate lactoferrin into hyaluronic acid coated liposomes by the lipid film method, followed by high pressure homogenization. Pharmacokinetic and pharmacodynamic profiles were evaluated in vitro and ex vivo. Cytotoxicity and ocular tolerance were assayed both in vitro and in vivo using New Zealand rabbits, as well as dry eye and anti-inflammatory treatments. LF loaded liposomes showed an average size of 90 nm, monomodal population, positive surface charge and a high molecular weight protein encapsulation of 53%. Biopharmaceutical behaviour was enhanced by the nanocarrier, and any cytotoxic effect was studied in human corneal epithelial cells. Developed liposomes revealed the ability to reverse dry eye symptoms and possess anti-inflammatory efficacy, without inducing ocular irritation. Hence, lactoferrin loaded liposomes could offer an innovative nanotechnological tool as suitable approach in the treatment of DED.

scholarly journals Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndrome

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Jeffrey Voigt
Keyword(s):  
Dry Eye ◽  
Amniotic Membrane ◽  
Cyclosporine A ◽  
Cost Utility ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Base Case ◽  
Societal Costs ◽  
One Year ◽  
Topical Medications

Abstract Background The purpose is to perform a cost effectiveness analysis amniotic membrane vs. topical medications in the use of treating dry eye disease. A cost effectiveness analysis comparing amniotic membrane + other topical medications to topical cyclosporine A + other topical medications was evaluated using accepted decision tree modeling software. Methods TreeAge Pro 2019 software was used to evaluate the base case costs over a one year timeframe. Sensitivity analysis was performed on those variables which had the greatest effect on choosing one therapy versus the other based on cost. Monte Carlo simulation was run 1,000 times to determine the most effective, least costly alternative. Costs were evaluated from a societal level (direct + indirect). Quality of life utility scores were evaluated using known time tradeoffs from prior studies (scale 0–1; with 1 being perfect vision). Results Over a one year timeframe, the base case demonstrated that amniotic membrane + topical medications was the less expensive alternative and provided for incremental utilities versus topical cyclosporine + other medications (Cost/utility: $18,275/0.78 vs. $20,740/0.74). If examining direct costs only, topical cyclosporine was the least expensive option over a one year timeframe: $4,112 vs. $10,300. Sensitivity analysis demonstrated that in order for topical cyclosporine to be the less expensive alternative the following variables would need to be: < 68 days productivity lost; < $161 productivity lost/day; > 79% of amniotic membrane implants would need to be re-implanted at month 4 (for whatever reason); > $2677 per amniotic membrane implant procedure (Medicare reimbursement rate); > 96% positive response to topical cyclosporine A at month 4; > 58% positive response to topical cyclosporine A at month 6 and; < 54% probability clinical improvement with amniotic membrane. Monte Carlo simulation demonstrated that amniotic membrane was the less costly, most effective alternative 91.5% of the time. Conclusion Based on improved outcomes using amniotic membrane, patient productivity was improved resulting in lower societal costs (less days lost from work). When considering the untoward effects of dry eye disease on societal costs, an improvement of the dry eye disease condition was accomplished most often with amniotic membrane.

Synergistically dual-functional nano eye-drops for simultaneous anti-inflammatory and anti-oxidative treatment of dry eye disease

Nanoscale ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 5580-5594 ◽  
Author(s):  
Yu-Jia Li ◽  
Li-Jyuan Luo ◽  
Scott G. Harroun ◽  
Shih-Chun Wei ◽  
Binesh Unnikrishnan ◽  
...  
Keyword(s):  
Gold Nanoparticles ◽  
Dry Eye ◽  
Dry Eye Disease ◽  
Rapid Recovery ◽  
Eye Disease ◽  
Eye Drops ◽  
Oxidative Treatment ◽  
Dual Functional ◽  
Anti Inflammatory

Poly(catechin)-capped gold nanoparticles carrying amfenac exhibit superior anti-inflammatory/anti-oxidative properties for rapid recovery from dry eye.

Sign in / Sign up

Export Citation Format

Share Document